Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Haozhou Tan"'
Autor:
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, Xiaoming Zhang, Ryan T. Morgan, Xiujun Zhang, Lian M. C. Jacobs, Shane G. Butler, Maura V. Gongora, John Choy, Xufang Deng, Yu Chen, Jun Wang
Publikováno v:
ACS Central Science, Vol 9, Iss 8, Pp 1658-1669 (2023)
Externí odkaz:
https://doaj.org/article/05a36a36b769471388ffab230a57b808
Autor:
Jin Ou, Eric M Lewandowski, Yanmei Hu, Austin A Lipinski, Ali Aljasser, Mariliz Colon-Ascanio, Ryan T Morgan, Lian M C Jacobs, Xiujun Zhang, Melissa J Bikowitz, Paul R Langlais, Haozhou Tan, Jun Wang, Yu Chen, John S Choy
Publikováno v:
PLoS Pathogens, Vol 19, Iss 8, p e1011592 (2023)
The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As Mpro inhibitor use increases, drug resistant mutations will li
Externí odkaz:
https://doaj.org/article/39ca587144e144418e7e1eb6c544ee20
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 4, Pp 1636-1651 (2022)
SARS-CoV-2 main protease (Mpro) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target spec
Externí odkaz:
https://doaj.org/article/90e935f2a53a452db3183c1acd1643a3
Autor:
C. Joaquín Cáceres, Yanmei Hu, Stivalis Cárdenas-García, Xiangmeng Wu, Haozhou Tan, Silvia Carnaccini, L. Claire Gay, Ginger Geiger, Chunlong Ma, Qing-Yu Zhang, Daniela Rajao, Daniel R. Perez, Jun Wang
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 1832-1848 (2021)
Seasonal influenza A virus (IAV) infections are among the most important global health problems. FDA-approved antiviral therapies against IAV include neuraminidase inhibitors, M2 inhibitors, and polymerase inhibitor baloxavir. Resistance against adam
Externí odkaz:
https://doaj.org/article/bca2a8c909e4481fa1b4630958e72308
Publikováno v:
Physical Chemistry Chemical Physics (PCCP); 8/14/2024, Vol. 26 Issue 30, p20629-20644, 16p
Publikováno v:
Journal of Medicinal Chemistry. 66:4468-4490
Autor:
Joshua Frost, Michael J. Rudy, J. Smith Leser, Haozhou Tan, Yanmei Hu, Jun Wang, Penny Clarke, Kenneth L. Tyler
Publikováno v:
Journal of Virology. 97
Recent outbreaks of EV-D68 in 2014, 2016, and 2018 have resulted in over 600 cases of a paralytic illness that is known as AFM. AFM is a predominantly pediatric disease with no FDA-approved treatment, and many patients show minimal recovery from limb
Publikováno v:
Medicinal Chemistry Research. 31:1147-1153
The COVID-19 pandemic spurred a broad interest in antiviral drug discovery. The SARS-CoV-2 main protease (Mpro) and papain-like protease (PLpro) are attractive antiviral drug targets given their vital roles in viral replication and modulation of host
Publikováno v:
Acta Pharmaceutica Sinica. B
SARS-CoV-2 main protease (Mpro) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target spec
Autor:
Haozhou Tan, Xiangzhi Meng, Maura V Gongora, Michael Dominic Sacco, Fushun Zhang, Yanmei Hu, Yan Xiang, Zilei Xia, Yu Chen, Juliana Choza, Janice Jang, Michael T. Marty, Chunlong Ma, Jun Wang, Julia Alma Townsend, Xiujun Zhang
Publikováno v:
Journal of the American Chemical Society
The main protease (Mpro) is a validated antiviral drug target of SARS-CoV-2. A number of Mpro inhibitors have now advanced to animal model study and human clinical trials. However, one issue yet to be addressed is the target selectivity over host pro